Ambivalence about supervised injection facilities among community stakeholders by unknown
Strike et al. Harm Reduction Journal  (2015) 12:26 
DOI 10.1186/s12954-015-0060-3BRIEF REPORT Open AccessAmbivalence about supervised injection
facilities among community stakeholders
Carol Strike1,2* , Tara Marie Watson1, Gillian Kolla1, Rebecca Penn1 and Ahmed M. Bayoumi3,4,5,6Abstract
Background: Community stakeholders express a range of opinions about supervised injection facilities (SIFs). We
sought to identify reasons for ambivalence about SIFs amongst community stakeholders in two Canadian cities.
Findings: We used purposive sampling methods to recruit various stakeholder representatives (n = 141) for key
informant interviews or focus group discussions. Data were analyzed using a thematic process. We identified seven
reasons for ambivalence about SIFs: lack of personal knowledge of evidence about SIFs; concern that SIF goals are
too narrow and the need for a comprehensive response to drug use; uncertainty that the community drug
problem is large enough to warrant a SIF(s); the need to know more about the “right” places to locate a SIF(s) to
avoid damaging communities or businesses; worry that a SIF(s) will renew problems that existed prior to
gentrification; concern that resources for drug use prevention and treatment efforts will be diverted to pay for a
SIF(s); and concern that SIF implementation must include evaluation, community consultation, and an explicit
commitment to discontinue a SIF(s) in the event of adverse outcomes.
Conclusions: Stakeholders desire evidence about potential SIF impacts relevant to local contexts and that
addresses perceived potential harms. Stakeholders would also like to see SIFs situated within a comprehensive
response to drug use. Future research should determine the relative importance of these concerns and optimal
approaches to address them to help guide decision-making about SIFs.
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Introduction
Public opinion is an important factor to consider in policy
making [1], including drug policy [2, 3]. However, public
opinion sometimes runs counter to scientific evidence [4].
This situation is reflected in studies showing that super-
vised injection facilities (SIFs), designed to reduce injection
drug use-related health problems, remain controversial
among some stakeholders (e.g., residents, business owners,
politicians, and police). Despite evidence to the contrary,
some stakeholders believe that SIFs promote initiation of
injection drug use, endorse continued drug use at the ex-
pense of encouraging entry into drug treatment, and/or
promote congregation of people who use and sell drugs* Correspondence: carol.strike@utoronto.ca
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[5, 6]. We previously reported findings showing that public
support for SIFs in Ontario, Canada increased between
2003 and 2009 [7]. However, we also reported that the ma-
jority of the public continued to hold ambivalent opinions
about SIF implementation [7].
In cities where some stakeholders are currently advo-
cating for SIFs (e.g., New York, San Francisco, Toronto,
Ottawa, and Montreal) [8–10], addressing public am-
bivalence may be important because decision makers are
more likely to act when public opinion is supportive of
policies [3]. In this brief report, we build upon and sup-
plement previous analyses of ambivalent attitudes within
the general public [7] with qualitative data analyses to
identify potential underlying reasons for SIF ambivalence
among community stakeholders.
Methods, ethics and consent
In Toronto and Ottawa, we used purposive methods to
recruit stakeholders (n = 141; 61 in Toronto and 80 inis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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diction services, public health, law enforcement, fire and
ambulance services, and housing and social services, as
well as local residents and business representatives. To
align with our analyses of public opinion data and in the
interests of brevity, this sub-analysis of data focuses on
these stakeholders. We also recruited people who use
drugs (n = 95, including people who inject drugs, people
who smoke drugs like crack cocaine, and those who use
drugs in both ways) as part of the larger mixed-methods
study. Their opinions about supervised consumption de-
sign preferences and SIF policy are reported elsewhere
[11, 12]. In the study design, we proposed to recruit
equal numbers from each city; however, during recruit-
ment a large, multi-stakeholder, community group inter-
ested in public safety issues asked the investigators to
conduct focus groups with them. Given that this group
represented a similar range of stakeholders of interest
for our study, we granted their request. This study was
approved by the research ethics boards at St. Michael’s
Hospital and the Centre for Addiction and Mental
Health. We have previously provided more details about
participant recruitment methods [12].
We used an iterative approach to data collection and
thematic analyses informed by a grounded theory ap-
proach [13]. Members of the research team designed the
interview and focus group guides which were pilot tested
during initial consultations with participants. Refine-
ments to question wording and new questions were
added to the guides based on participant responses dur-
ing these early interviews and focus groups. We con-
ducted one-on-one key informant interviews (n = 26)
and focus group discussions (n = 115 people) between
December 2008 and January 2010. All participants pro-
vided informed consent, including permission to use
anonymized quotes from their data, and were offered a
$25 CAD honorarium. All interviews and focus groups
were audio-recorded. During all interviews and focus
groups, participants were asked questions about the fol-
lowing topics: perceived drug use in their communities;
the benefits and drawbacks of SIFs; potential SIF loca-
tions and policies; and other approaches to address drug
use.
Transcripts were stored and coded using NVivo 8 soft-
ware. An analytic sub-team developed a codebook that
contained key themes and subthemes of interest. Coding
meetings were held with sub-team members where any
coding discrepancies or suggestions for new codebook
themes were discussed and resolved by group consensus.
Results
In this analysis, we focus on seven reasons for ambiva-
lence about SIFs. Sending the “wrong message” and risk
of increased drug use and/or injecting were concernsexpressed by some participants, but were typically done
so in relation to outright dismissal or disagreement with
SIFs, rather than ambivalence. Please see Table 1 for a
summary of the reasons for ambivalence and supporting
excerpts from the data. With the exception of the police
in this study, who were uniformly opposed to SIFs [14],
most participants voiced ambivalent opinions about SIF
implementation: e.g., “I sit on the fence”, “I’m torn”, and
“I’m up in the air with it”. Positive and negative SIF out-
comes (e.g., reductions in HIV prevalence in the com-
munity; increases in drug-related crime around the
facility) were positioned as crucial to the acceptance or
rejection of SIFs, and stakeholder ambivalence was par-
tially linked to a lack of knowledge about such outcomes
and evidence. Citing lack of sufficient personal know-
ledge, some stakeholders refused to offer any opinions
about SIFs, including a public official in Toronto who
said, “I don’t feel like I have all of the information that I
would need to make a sound recommendation.”
Ambivalence was also linked to perceptions that SIF
goals are too narrow and a comprehensive strategy
for drug-related problems, which may include SIFs, is
necessary. While some participants could be swayed
towards accepting SIFs as part of a comprehensive
strategy, there was no consensus about what “compre-
hensive” included. Suggestions ranged widely, from
simply adding new SIF objectives (e.g., include abstin-
ence) to multi-faceted approaches (e.g., increased ser-
vices for drug use prevention, treatment, primary
care, mental health, and housing). While reasons for
ambivalence were generally the same in both cities,
more Ottawa than Toronto participants spoke about
concerns that a SIF would “siphon” away resources
for drug treatment. Further, ambivalent stakeholders
framed SIFs as a solution for cities said to have “dev-
astating” drug problems (e.g., the Downtown Eastside
in Vancouver, Canada) and that did not match the
problems they knew about or experienced in their
communities.
While ambivalent participants said that there might
be a “right place” for SIFs, they did not suggest pre-
cise locations but rather excluded locations near their
homes or businesses, often out of concern regarding
damaging outcomes: e.g., “It's a good idea if it's not
in my neighbourhood.” In neighbourhoods where gen-
trification was attributed to a reduction in local drug-
related problems, some participants worried that a
SIF(s) would renew these problems. A few ambivalent
participants suggested that multiple or mobile SIFs
would better address the dispersed nature of drug use
in their city and alleviate concerns about congregation
of drug users and drug dealing around a SIF(s).
Lastly, before offering their support to SIFs, ambiva-
lent participants stated that they wanted assurances that
Table 1 Reasons for ambivalence about SIFS
Reason Illustrative excerpts
1. Lack of personal knowledge of evidence about SIFs It’s easy just to say… well I wouldn’t want one because I’m going to have all
these people wandering around downtown as high as kites. But then once
you find out, well actually no, because this is set in place so that doesn’t
happen… it could change people’s opinions, and they might be like, “Okay,
well I can see the benefit of that then.” Knowledge can change everything.
(Toronto business owner)
2. Concern that SIF goals are too narrow and need to be located within
a comprehensive response to drug use (“Comprehensive” defined with a
range of suggestions)
So there’s got to be more of a point to this, I think, than just a clean place
for these drugs…The thing for us is that we might be able to convince half
of these people to stop. (Ottawa ambulance personnel)
I think we’re not serving people well if we just focus on their addiction, if we
don’t also provide mental health services. … I think the community would be
more receptive, from our drug strategy work, as long as harm reduction was
connected to treatment options and housing and all of those other things…
than if it’s just kind of seen as giving up on people, and just warehousing
them in this little place downtown, not that that’s maybe the perception
often I think. (Ottawa community/service provider)
3. Uncertainty that the community drug problem is large enough to
warrant SIF implementation
We haven’t hit that crisis point, as Vancouver has hit… where they were
doing it [injecting] in the daytime, around strollers and stuff. Get them off the
street. We haven’t hit that point yet, so why would we even put all our
money into that when we haven’t gotten there yet. (Toronto ambulance
personnel)
4. Need to know more about the so-called “right” places to locate SIFs to
avoid damaging communities or businesses
I struggle because [I] can see the potential benefits but an SIF would have a
negative impact. The local [methadone maintenance treatment] clinic has
created problems with thefts etc. [SIFs] would damage business. (Toronto
resident)
I might kick myself in the ass for saying this, but I might consider a mobile
facility that, it’s not stationed in one place, but maybe they don’t have to be
right on the main street… I’m opposed to this, but I would consider a
mobile. (Toronto resident)
5. Worry that a SIF(s) will renew problems that existed prior to
neighbourhood gentrification
[W]e had swarms of drug dealers and drug users, and we don’t want to go
back there again (Toronto resident)
6. Concern that resources for drug use prevention and treatment will be
diverted to pay for SIFs
And as a matter of fact, if it in any way compromised the integrity of things
like methadone clinics, and other types of treatment options that are out
there, I wouldn’t support it. (Toronto health care worker)
…if they take away resources from other things. So it does depend. (Ottawa
city employee)
7. Concern that SIF implementation must include evaluation and
community consultation, and explicit commitment to discontinue a
SIF(s) in the event of adverse outcomes
I would want some kind of assurance, some accountability on the part of the
people who are running these, saying that give them a time, and if it’s not
working, then they have to agree that we can sort of shut it down. Just to
actually say a permanent site, I’m totally against it. If it was something on a
temporary basis, on a contract basis, I would support it. (Toronto resident)
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and opportunities for community consultation regarding
SIF continuation or closure.
Discussion
Our data show that community stakeholders who ex-
press ambivalence towards SIFs desire evidence about
potential SIF impacts relevant to local contexts and that
addresses perceived potential harms. These stakeholders
would also prefer to see SIFs as part of a comprehensive
drug strategy that ensures dedicated resource allocation
for drug use prevention and drug treatment programs.
During the focus groups, the moderators were often
asked by participants to provide a rationale for SIFs
given that needle and syringe programs (NSPs) are avail-
able in numerous locations in both Toronto and Ottawa(unpublished observations; Strike, Watson, and Kolla).
These questions demonstrate lack of knowledge about
the additional benefits of SIFs, over and above NSPs.
Also, concerns that a SIF(s) would “siphon” away funds
from drug treatment programs suggest lack of under-
standing of the ways in which SIF services can comple-
ment drug treatment programs [15].
There are several limitations to this study, including
the purposive recruitment of participants. However, the
aim of this sub-study was to complement existing re-
ports of public opinion [7] with deeper exploration of
stakeholders’ perspectives on SIF implementation. The
sample size for this sub-study is large compared to other
qualitative studies [16] and the repetition of reasons for
ambivalence across focus groups and key informant inter-
views suggests that saturation was reached. These features
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consultations took place in two cities without operational
SIFs [9] and as such these results may not be generalizable
to locations where SIFs have already been established. In
future surveys of public opinion, including questions
about the reasons for ambivalent opinions could provide
representative estimates of such opinions and help esti-
mate the relative importance of the reasons for ambiva-
lence we outline above.
For those in favour of SIF implementation, an out-
standing question for research and policy remains on
the table – how might we better address ambivalence
and encourage community stakeholders to support SIFs?
A likely and important barrier to changing ambivalent
opinions is continued stigma and discrimination towards
people who use drugs and harm reduction services [17, 18].
Overcoming this stigmatization will take concentrated
effort and broad community education. Making additional
gains in SIF acceptance, in particular, appears to need on-
going processes of “policy mobilization” championed by
local advocates and experts [19]. Our analysis offers a snap-
shot of reasons that may underlie SIF ambivalence that may
ultimately help or hinder such processes in Canadian and
international jurisdictions. The evidence we present is espe-
cially timely in Canada where very recently a bill, Bill C-2,
that seeks to restrict the opening of new SIFs has received
royal assent [20]. The bill outlines a lengthy list of criteria –
with emphasis on broad community support – that must
be met before the requisite legal exemption for a SIF can be
granted [21, 22].
In short, we report evidence from a large, mixed-
methods study designed by a group of multidisciplinary
experts who received competitive, external funding for
this research and who also benefited from access to a
public opinion study [7]. These resources and the scope
of our study are not easy to replicate. Other communities
without access to the same level of scientific expertise and
financial resources may face difficulties accumulating the
breadth of data required under Bill C-2 or similar legisla-
tion that may exist elsewhere which, in turn, may hamper
their ability to move forward with evidence-based harm
reduction programs.
Abbreviation
SIFs: Supervised injection facilities.
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